IL17A and melanoma: The pooled melanoma incidence rates were: 0.06 (95% CI, 0.02–0.18) per 100 patient-years for IL-17 inhibitors, 0.10 (95% CI, 0.05–0.21) for IL-23 inhibitors, and 0.09 (95% CI, 0.03–0.28) for JAK inhibitors (52).